INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SKIN
SUSTAINABILITY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
MEDIA PACK
CONTRIBUTE
Subscribe
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SKIN
SUSTAINABILITY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
MEDIA PACK
CONTRIBUTE
SEARCH
SEARCH
advanced search
INJECTION
INJECTION
Bill Guilliouma
Noble
SUPPORTING IMPROVED PATIENT ONBOARDING & ADHERENCE WITH TRAINING SOLUTIONS
Bill Guilliouma looks at the role of platform training solutions for patient onboarding and adherence to treatment regimens.
EXPERT VIEW
Beth Crandall
EU MDR DEADLINE DELAY: WHAT DOES IT MEAN FOR THE MEDICAL DEVICE INDUSTRY?
With the compliance deadline for the EU Medical Device Regulation recently delayed by a year due to the novel coronavirus pandemic, Beth Crandall looks at what it means for the medical device industry.
EXPERT VIEW
Nigel Theobald
SILICA RE-EMERGES AS POTENTIAL NUCLEIC ACID DELIVERY VECTOR
Nigel Theobald looks at the challenges of oligonucleotide delivery and explores approaches to overcome them.
Joe Reynolds
Noble
Telemedicine gains acceptance amid the Covid-19 pandemic
Noble highlights how telemedicine is poised to become a mainstream alternative to the traditional in-person methods of care delivery, with the covid-19 pandemic easing barriers to acceptance and introducing patients to the safety and convenience of telehealth technology.
MedinCell investigating role of long-acting antivirals to break chain of SARS-COV-2 viral transmission
With evidence indicating that the established antiparasitic ivermectin can kill coronavirus in a laboratory setting in under 48 hours, MedinCell has published data showing that long-acting formulations of ivermectin can be designed with varying doses and durations with its BEPO® technology and is investigating whether a long-acting product could be effective in breaking the chain of viral transmission.
Lexaria Bioscience Expands Pharma Division for development of Lipophilic Antivirals against COVID-19
Lexaria is to investigate how its patented DehydraTECH drug delivery technology could enhance delivery and effectiveness of certain antiviral drugs in the fight against coronavirus disease COVID-19. Lexaria intends to expand collaboration with leading laboratories as soon as possible.
PREFILLED SYRINGES
Gene Rhode Fuensalida Pantig
SHL Medical
ADDRESSING COMPLEX BIOLOGICS WITH RATIONAL DRUG DEVICE DESIGN
Gene Rhode Fuensalida Pantig reviews drug development over the years, the discovery of biologics as therapeutic agents and the emergence of autoinjectors, in correspondence with Hans Lin, PhD, a Research Fellow from Academia Sinica, Taiwan.
PREFILLED SYRINGES
Joe Reynolds
Noble
ENHANCING THE PATIENT EXPERIENCE FOR SELF-INJECTION SYSTEMS
The complexity of injectable treatment regimens for chronic diseases means onboarding aids can be integral to disease management. Joe Reynolds discusses the role of demonstration devices in improving the patient experience and adherence.
WEARABLES
Jennifer Estep
Enable Injections
DRUG DELIVERY DESIGNED TO IMPROVE THE PATIENT EXPERIENCE
Jennifer King looks at the delivery challenges of novel therapies for chronic diseases using a specific patient’s story as an example, going on to highlight the ways in which a novel device approach could make all the difference for patients.
INJECTION
Dr Andreas Schneider
Ypsomed
HOW USERS DISTINGUISH BETWEEN SELF-INJECTION DEVICE PLATFORM VARIANTS
Andreas Schneider highlights how the ever-increasing interest in device platforms raises concerns around the broad availability of lookalike autoinjectors that may result in inappropriate medication usage. He summarises a recent empirical study
1
providing insights into which device attributes drive device distinguishability.
PREFILLED SYRINGES
Shota Arakawa
Mitsubishi Gas Chemical
OXYCAPT MULTILAYER PLASTIC VIAL AND SYRINGE
Shota Arakawa and Tomohiro Suzuki, discuss the benefits of the OXYCAPT™ multilayer plastic vial and syringe for the rapidly growing field of biologics and regenerative medicines.
EXPERT VIEW
Jos van Noort
CHOOSING THE RIGHT LABEL MATERIAL FOR PREFILLED SYRINGES
Jos van Noort outlines some of the key factors that must be taken into consideration when selecting a label for prefillable syringes.
WEARABLES
Thomas Mayer
Sonceboz
NEXT-GENERATION WEARABLE DELIVERY DEVICES FOR LARGE-VOLUME BIOLOGICS
Thomas Mayer discusses Sonceboz’s platform of wearable injection devices for large-volume biologics, which can follow drugs from clinical trials to commercial phase through lifecycle management, which reduces risk and speeds time to market.
EXPERT VIEW
Elizma Parry
EU MDR: ANCILLARY DELIVERY DEVICES FACE EQUAL SCRUTINY TO STANDALONE MEDICAL DEVICES
Elizma Parry offers her expertise and practical guidance to businesses hoping to achieve a CE mark for a medical device, with new EU regulations being implemented this year.
PREFILLED SYRINGES
Wolfgang Moersch
ZwickRoell
PRODUCT SHOWCASE: ZwickRoell Parenteral Device Testing Platform
ZwickRoell offers a wide variety of standardised test fixtures for parenteral devices including, described here: testing prefilled syringes to ISO 11040-4, -6 & -8; testing of Luer/Luer lock connections; serial, parallel and fully automatic syringe testing; and traceable, tamper-proof test results.
INJECTION
Tom Oakley
Midas Pharma
DEVELOPMENT OF A NEW HIGH-PERFORMANCE AUTOINJECTOR
Tom Oakley and Sigrid Saaler-Reinhardt discuss the development of the Midas Pharma’s NIS cartridge-based autoinjector.
EXPERT VIEW
George I’ons
PREFILLED SAFETY SYRINGE MARKET THRIVES AMID SELF-ADMINISTRATION TREND
George I’ons looks at how the growing trend of patient self-administration is driving demand for prefilled safety syringes.
EXPERT VIEW
Dr Paolo Fiorini
LARGE-VOLUME INJECTORS: RISE IN BIOLOGICS BRINGS CHALLENGES
Developing devices capable of delivering highly viscous biologic drug formulations at high volumes does not come without its challenges. Paolo Fiorini, Gerard Linnane, Michael Kiely, Maciej Grygorczuk and Joshua Coyne discuss these challenges and the merits of various drive solutions.
INJECTION
Séverine Duband
Nemera
LEVERAGING THE PATIENT JOURNEY TO OPTIMISE DEVICE USE AT HOME
Séverine Duband and Mark Tunkel discuss the importance of device optimisation to increase patient safety during self-administration of medication.
WEARABLES
Dr Temitope Sodunke
BD (Becton Dickinson & Company)
ADDRESSING THE EVOLVING NEEDS OF VARIABLE DRUG DELIVERY REGIMENS
Temitope Sodunke introduces the BD Evolve™ On-body Injector and describes how the device is designed specifically to address the rapidly evolving needs of the pharma industry and meet patient requirements.
EXPERT VIEW
Steve Augustyn
HOW TO DESIGN A BODY-WORN INJECTOR
Body-worn injectors require you to understand your user, your drug and your technology – and there are numerous pitfalls for the unwary. Stephen Augustyn shares some insights.
INJECTION
Marino Kriheli
Equashield
THE NEED FOR CSTDS IN BOTH MANUAL AND AUTOMATED COMPOUNDING
Marino Kriheli discusses the benefits of using closed system transfer devices (CSTDs) in both manual and automated hazardous drugs compounding.
PREFILLED SYRINGES
Christian Helbig
SCHOTT Pharma
FINDING THE RIGHT PACKAGING FOR BIOLOGIC DRUGS
Christian Helbig introduces a new 2.25 mL version of SCHOTT’s syriQ BioPure
®
prefillable syringes designed specifically for the biologics market and, developed in partnership with WL Gore, the world’s first silicone-free glass syringe system.
INJECTION
David Fink
THE CHALLENGES OF A CHANGING MARKET & THE BENEFITS OF DEVELOPMENT FLEXIBILITY
David Fink and Sheila Trgovac describe how adopting a flexible development model in mid-to-late development brings benefits through to commercialisation, especially in the context of a changing market.
Prev
1
…
26
27
28
29
30
…
46
Next
Top
